嵌合型抗原受体T细胞治疗技术在B细胞肿瘤中的研究进展：第56届美国血液学会年会报道

Progress of chimeric antigen receptor T cell immunotherapy in B cell hematologic malignancies： reports from the 56th American Society of Hematology annual meeting

嵌合型抗原受体T细胞（chimeric antigen receptor Tcell，CAR—T）在B细胞肿瘤临床试验中已经显示了良好的前景，但是CAR—T的设计、肿瘤抗原的选择、T细胞的来源、CAR-T的临床应用策略等还有待进一步开发完善。CAR—T免疫细胞治疗技术是2014年第56届美国血液学会（ASH）年会的热点话题之一，其基础研究及临床试验均有突破性进展。

Chimeric antigen receptor T cell （CAR-T） therapy has shown promising perspective in clinical trails of B cell hematologic malignancies. Meanwhile, this therapy still need to be farther improved in the following aspects： design of CAR-T, cancer antigens selection, T cells origin, and clinical application strategy. CAR-T immunotherapy is one of hot topics in the 56th American Society of Hematology （ASH） annual meeting. Some breakthroughs have been reported in both basic research and clinical trails.